Preprint · OA
via OpenAlex
Elderly patients with multiple myeloma: towards a frailty approach?
Sonja Zweegman, Monika Engelhardt, Alessandra Larocca
Current Opinion in Oncology · 2017 · ▲ 103 citations
Abstract
PURPOSE OF REVIEW: To describe how to better identify frail multiple myeloma patients and to treat them appropriately. RECENT FINDINGS: Proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib, and immunomodulatory agents (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, have significantly improved the outcome of multiple myeloma patients in the last decade. However, both in clinical trials and in daily clinical practice, elderly multiple myeloma patients have shown lesser benefit. This is mainly due to less stringent use of proteasome inhibitors and IMiDs, increased toxicity, and subsequent early discontinuation of therapy in elderly. SUMMARY: Multiple myeloma typically affects elderly patients. Approximately one-third of patients are older than 75 years at diagnosis. Moreover, at least 30% are frail, both due to disease-related symptoms and (age-related) decline in physical capacity, presence of comorbidities, frailty, polypharmacy, nutritional status, and cognitive impairment. Treatment regimens that are investigated in clinical trials for transplant-ineligible patients have largely been investigated in fit, rather than frail patients, the latter being typically excluded or highly underrepresented therein. Data on the feasibility and efficacy of current standards of care are therefore lacking in frail patients. Preliminary data suggest a higher toxicity and discontinuation rate, loss of efficacy, and impaired quality of life in frail patients. Geriatric assessment helps to identify frail patients according to their functional and cognitive status. Both the International Myeloma Working Group (IMWG)-frailty index and Revised Myeloma Comorbidity Index constitute recently proposed algorithms that easily identify intermediate-fit and frail patients. Ongoing and future clinical trials, specifically designed for frail patients, will hopefully define frailty-directed treatment selection.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1097/cco.0000000000000395
- Canonical
- link ↗
- Fetched
- 2026-07-25 MST
Cite this
APA
Zweegman, S., Engelhardt, M., & Larocca, A. (2017). Elderly patients with multiple myeloma: towards a frailty approach?. <em>Current Opinion in Oncology</em>. https://doi.org/10.1097/cco.0000000000000395
Vancouver
Zweegman S, Engelhardt M, Larocca A. Elderly patients with multiple myeloma: towards a frailty approach?. Current Opinion in Oncology. 2017. doi:10.1097/cco.0000000000000395.
BibTeX
@unpublished{sonja2017Elderl,
title = {Elderly patients with multiple myeloma: towards a frailty approach?},
author = {Sonja Zweegman and Monika Engelhardt and Alessandra Larocca},
journal = {Current Opinion in Oncology},
year = {2017},
doi = {10.1097/cco.0000000000000395},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Hellenic Oncology Research Group 2003
Open access · US-GOV
A Multicenter Randomized Phase II Study of Docetaxel Versus Vinorelbine as First-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)
Hospital de Clinicas de Porto Alegre 2024
Open access · US-GOV
The Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With Type 2 Diabetes Mellitus: a Randomized Clinical Trial.
Allergan 2011
Open access · US-GOV
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Revista Brasileira de Geriatria e Gerontologia 2017
Open access · CC-BY
Risk of death in elderly persons based on the frailty phenotype and the frailty index: a review study
Vestre Viken Hospital Trust 2024
Open access · US-GOV
INTEgRated Health CARE for Patients With Frailty and Heart Failure (INTERCARE-HF): Evaluation of an Innovation Project
University of Pisa 2023
Open access · US-GOV